A local retrospective observational study to evaluate the treatment patterns of mCRPC patients in Belgium treated with Radium-223 (BELFIGO)
The aim of this non interventional study is to describe the proportion of Belgian mCRPC patients which were treated with 1 to 4 and 5 to 6 Radium-223 injections and the patient characteristics which are potentially associated with this proportion.
- Patients with a diagnosis of castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases - All consecutive patients who started Radium-223 treatment between 22 December 2014 and 01 June 2017 - Availability of medical records during the observation period (22DEC2013 – 01JUN2018)
- Patients treated with Radium-223 for any reason before 22 December 2014 (for example an interventional trial) - Patients participated in an investigational program with interventions outside of routine clinical practice during the radium-223 treatment period - Patients received other radiopharmaceuticals for the systemic concomitant use for treatment of prostate cancer or for other use during the Radium-223 treatment period
Many Locations, Belgium
E-mail: [email protected]
Phone: (+)1-888-84 22937
A local retrospective observational study to evaluate the treatment patterns of mCRPC patients in Belgium treated with Radium-223